Angiotensin II (3-8), human

Cat. No.: HY-P1515: Data Sheet Handling Instructions
FAQs
Technical Support

Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT₁ receptor.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Custom Peptide Synthesis

Angiotensin II (3-8), human 화학구조

CAS No. : 12676-15-2

사이즈		재고
MOQ		Minimum order quantity
50 mg		견적 받기
100 mg		견적 받기
250 mg		견적 받기
Other size		견적 받기

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Angiotensin II (3-8), human:

Angiotensin II (3-8), human TFA

Other Forms of Angiotensin II (3-8), human:

Angiotensin II (3-8), human TFA In-stock

2 Publications Citing Use of MCE Angiotensin II (3-8), human

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Angiotensin Receptor Isoform Specific Products:

View All Isoforms

AT1 Receptor AT2 Receptor

Biological Activity
Protocol
순도&문서
References
고객리뷰

제품 설명	Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT₁ receptor.
IC₅₀ & Target	Angiotensin AT₁ receptor^[1]
In Vivo	Human Angiotensin II (3-8) causes endothelium-dependent renal cortical vasodilatation, in anaesthetized rats. At doses up to 125 pmol/kg, human Angiotensin II (3-8) is without any cardiovascular effects, but with doses of 1.25 and 12.5 nmol/kg there are dose-dependent increases in mean arterial blood pressure and reductions in renal and mesenteric flows and vascular conductances^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
분자량	774.91
화학식	C₄₀H₅₄N₈O₈
CAS No.	12676-15-2
Sequence	Val-Tyr-Ile-His-Pro-Phe
Sequence Shortening	VYIHPF
선적	Room temperature in continental US; may vary elsewhere.
보관	Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서	Data Sheet (281 KB) Handling Instructions (2659 KB)
References	[1]. Gardiner SM, et al. Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol. 1993 Sep;110(1):159-62. [Content Brief]

Animal Administration
^[1]

Rats^[1]
Male Long Evans rats (350-450 g) (n=7) are given increasing bolus doses of AII (1.25, 12.5 and 125 pmol/kg) or human Angiotensin II (3-8) (0.125, 1.25 and 12.5 nmol/kg) in random order, in the morning or afternoon of the same experimental day. Injections are separated by at least 20 min to allow variables to return to baseline^[1].

MCE 는 독립적으로 이러한 방법들의 정확성을 확인하지 않았습니다. 참고용으로만 봐주십시오.

References

[1]. Gardiner SM, et al. Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol. 1993 Sep;110(1):159-62. [Content Brief]